Tumor Heterogeneity: Is There Order in Variety?

Where order in variety we see, and where, though all things differ, all agree. When Alexander Pope wrote those lines in 1734 in his “Essay on Man” he most certainly did not have tumor heterogeneity in mind. Perhaps now, almost 300 years ...
Read more

Standardizing Standards in Digital Pathology

During the last year, I (Martin Kristensson- learn about me here) have spent more and more time on the deployment of our clinical diagnostic solutions, working closely with the European hospitals. When we began, I was surprised to discover how littl...
Read more

Denmark Leads the World in Highest Cancer Rates

Denmark Leads the World in Highest Cancer Rates
Yesterday, February 4th, was World Cancer Day and the WCRF International issued this excellent infographic on some insightful statistics around cancer.  Visiopharm is headquartered in Denmark, the country with the highest cancer rates in the wor...
Read more

Is Cost Effective Clinical Use of Digital Pathology Possible?

Clinical use of digital pathology remains a very hot topic in the pathology community. Although most pathologists and industry colleagues perceive that there is nothing very new to report since the FDA has not issued any guidance and no whole slide ...
Read more

An Extreme Makeover for Histopathology

The practice of histopathology faces several challenges; specifically an increasing number of cases that must be processed and diagnosed faster while reducing cost.  At the same time pathologists and scientists are challenged, especially on data...
Read more

Visiopharm and Omnyx Partner to Advance Cancer Diagnostics with Clinically Validated Image Analysis Algorithms for Pathologists

Visiopharm and Omnyx Partner to Advance Cancer Diagnostics with Clinically Validated Image Analysis Algorithms for Pathologists
Hoersholm, Denmark (PRWEB) October 15, 2013 Visiopharm a leader in Quantitative Digital Pathology and Omnyx LLC, a joint venture between GE Healthcare and UPMC a leader in digital pathology, partner to advance cancer diagnostics with clinically vali...
Read more